Archives of General Psychiatry

Journal Information
ISSN / EISSN : 0003990X / 15383636
Current Publisher: American Medical Association (AMA) (10.1001)
Total articles ≅ 10,674
Current Coverage
PUBMED
MEDLINE
MEDICUS
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Rachel G. Klein, Salvatore Mannuzza, María A. Ramos Olazagasti, Erica Roizen, Jesse A. Hutchison, Erin C. Lashua, F.Xavier Castellanos, Erica Roizen Belsky, Erin Lashua-Shriftman
Archives of General Psychiatry, Volume 69; doi:10.1001/archgenpsychiatry.2012.271

Archives of General Psychiatry, Volume 69; doi:10.1001/archgenpsychiatry.2011.1239

Archives of General Psychiatry, Volume 69; doi:10.1001/archpsyc.69.12.1192

Laura A. Thomas, Melissa A. Brotman, Eli J. Muhrer, Brooke H. Rosen, Brian L. Bones, Richard C. Reynolds, Christen M. DeVeney, Daniel S. Pine, Ellen Leibenluft
Archives of General Psychiatry, Volume 69, pp 1257-1266; doi:10.1001/archgenpsychiatry.2012.913

Abstract:
Pediatric bipolar disorder (BD) is diagnosed with increasing frequency,1 perhaps because some suggest that it presents as either severe nonepisodic irritability or episodic mania.2 This suggestion raises questions about clinical and pathophysiologic differences between these 2 presentations. To evaluate this, the phenotype of severe, nonepisodic irritability was operationalized as severe mood dysregulation (SMD).2 Family history3 and longitudinal data4,5 suggest that BD and SMD are dissociable phenotypes, whereas behavioral data find similarities in facial information processing.6-9 Imaging studies can elucidate similarities and differences in neural mediators of such information-processing findings.10,11 In this study, we compared blood oxygenation level–dependent (BOLD) activation patterns during the presentation of parametrically morphed emotional faces in patients with BD or SMD and healthy volunteers (HVs).
Michael F. Green, Gerhard Hellemann, William P. Horan, Junghee Lee, Jonathan K. Wynn
Archives of General Psychiatry, Volume 69, pp 1216-1224; doi:10.1001/archgenpsychiatry.2012.652

Abstract:
Schizophrenia treatment research has moved well past management of psychotic symptoms to the more ambitious, and to the patient more personally meaningful, goal of ‘‘recovery.” In general, recovery refers to achievement of independent living, vocational or educational activities, and satisfying interpersonal relationships.1,2 To achieve recovery, it is first necessary to identify the key determinants of poor functioning that interfere with successful adaptation. Functional outcome generally refers to the degree of success that a person has with social connections, vocational pursuits, and degree of independent living. Several determinants have been identified, with considerable focus on neurocognition and negative symptoms.3-6 However, other factors, including perception, social cognition, functional capacity, and defeatist beliefs, also influence functional success achieved by people with schizophrenia.7-10 The goal of the current study was to evaluate how well data from a large sample of patients fit a single-pathway model that runs from visual perception through intervening variables to functional outcome.
James C. Harris
Archives of General Psychiatry, Volume 69, pp 1194-1194; doi:10.1001/archgenpsychiatry.2012.111

The publisher has not yet granted permission to display this abstract.
Carl Ernst, Christian R. Marshall, Yiping Shen, Kay Metcalfe, Jill Rosenfeld, Jennelle C. Hodge, Alcy Torres, Ian Blumenthal, Colby Chiang, Vamsee Pillalamarri, et al.
Archives of General Psychiatry, Volume 69, pp 1238-1246; doi:10.1001/archgenpsychiatry.2012.660

Abstract:
Brain-derived neurotrophic factor (BDNF) is a nervous system growth factor that plays a critical role in synaptic modeling, neurodevelopment, and cell signaling.1 It is a member of the nerve growth factor family with structural similarity to nerve growth factor and neurotrophin 3 and neurotrophin 4 and structural differences distinct from the other nervous system growth factor families, which include fibroblast growth factor, insulin-like growth factor, transforming growth factor β, and cytokine families.2 While all nervous system growth factors support neurodevelopment, BDNF has been singularly implicated for its role in obesity, pain, and memory.3-7 The protein is encoded by BDNF, located on the short arm of chromosome 11 at band p14, where a polymorphic variant at codon 66 specifies either valine or methionine and is thought to affect processing of proBDNF to BDNF. This locus has been considered as a risk factor for schizophrenia, major depression, attention-deficit/hyperactivity disorder, bipolar disorder, and many other psychopathologies,8,9 primarily from association-based studies evaluating the nonsynonymous Val66Met variant and studies comprising cases with deletions on 11p associated with deletions in WT1 and PAX6.10,11
Mette Odegaard Nielsen, Egill Rostrup, Sanne Wulff, Nikolaj Bak, Brian Villumsen Broberg, Henrik Lublin, Shitij Kapur, Birte Glenthoj
Archives of General Psychiatry, Volume 69, pp 1195-1204; doi:10.1001/archgenpsychiatry.2012.847

The publisher has not yet granted permission to display this abstract.
Jose Mathews, John W. Newcomer, Jennifer R. Mathews, Christina L. Fales, Kathy J. Pierce, Brandon K. Akers, Ioana Marcu, Deanna M. Barch
Archives of General Psychiatry, Volume 69, pp 1226-1237; doi:10.1001/archgenpsychiatry.2012.934

The publisher has not yet granted permission to display this abstract.
Mark Olfson, Carlos Blanco, Shang-Min Liu, Shuai Wang, Christoph U. Correll
Archives of General Psychiatry, Volume 69, pp 1247-1256; doi:10.1001/archgenpsychiatry.2012.647

Abstract:
Over the past several years, an increasing number of adults and children in the United States have been treated with antipsychotic medications.1,2 Antipsychotics are now among the most commonly prescribed and costly classes of medications.3 In adults, antipsychotic medications have demonstrated efficacy and have been approved by the Food and Drug Administration (FDA) as a primary treatment for schizophrenia4,5 and bipolar disorder6,7 and as an adjunctive treatment for major depressive disorder.8 In children and adolescents, antipsychotics are indicated for irritability associated with autistic disorder (5-16 years), tics and vocal utterances of Tourette syndrome and bipolar mania (10-17 years), and schizophrenia (13-17 years).9
Back to Top Top